Panbela Therapeuticsの評価平均
Panbela Therapeuticsの評価平均は何ですか。
Panbela Therapeutics Inc.の評価平均は2.50です。
評価平均の定義は何ですか。
Recommendation meanは、株式のアナリストの格付けの平均値で、1.0(強い買い)から5.0(強い売り)の範囲です。
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
NASDAQのセクタHealth Careにおける評価平均の企業と比べるPanbela Therapeutics
Panbela Therapeuticsは何をしますか。
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Panbela Therapeuticsと類似の評価平均
- Revvityの評価平均は2.47です。
- Cardinal Healthの評価平均は2.47です。
- Cintasの評価平均は2.47です。
- Textronの評価平均は2.47です。
- Ralph Lauren Corpの評価平均は2.48です。
- NOV Incの評価平均は2.48です。
- Panbela Therapeuticsの評価平均は2.50です。
- Landbridgeの評価平均は2.52です。
- Urban Outfittersの評価平均は2.52です。
- Wells Fargo & Coの評価平均は2.52です。
- United Airlines Incの評価平均は2.52です。
- Cognizant Technology Solutionsの評価平均は2.52です。
- Grupo Aeroportuario Del Pacifico SAB de CVの評価平均は2.53です。